Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2013 Earnings Results

Alnylam Pharmaceuticals Misses on EPS, Stock Up 1.39%

Alnylam Pharmaceuticals reported a loss that was slightly worse than expected, which typically raises concerns among investors. However, the stock rose by 1.39%, likely due to broader market trends or investor optimism about future developments. The lack of revenue data and guidance leaves some uncertainty about the company's short-term outlook.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.51	N/A	-6.25%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed caution about the current market conditions. They reiterated their focus on long-term objectives despite recent setbacks.

Management acknowledged the challenges faced during the quarter.

They emphasized ongoing commitment to their strategic goals.

No specific updates were provided regarding future product launches.

Alnylam Pharmaceuticals Misses on EPS, Stock Up 1.39%

Key numbers

Management commentary

Alnylam Pharmaceuticals, Inc.

More earnings this week

Alnylam Pharmaceuticals Misses on EPS, Stock Up 1.39%

Key numbers

Management commentary